A5041581672- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- Breast Implant and Reconstruction
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Cancer and Skin Lesions
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Nutrition, Genetics, and Disease
- PI3K/AKT/mTOR signaling in cancer
- AI in cancer detection
- Advanced Biosensing Techniques and Applications
- Gene expression and cancer classification
- Cytokine Signaling Pathways and Interactions
- Cancer-related Molecular Pathways
- Epigenetics and DNA Methylation
- 3D Printing in Biomedical Research
- Genomics and Chromatin Dynamics
Western General Hospital
2013-2025
Cognition, Santé, Société
2019-2023
Edinburgh Cancer Research
2010-2021
Mount Vernon Cancer Centre
2019
National Institute for Health Research
2019
Cambridge University Hospitals NHS Foundation Trust
2019
University College London
2019
Total (France)
2019
Western Infirmary
1985-2018
Ontario Institute for Cancer Research
2018
Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment early breast cancer. We investigated prospectively predictive biomarkers anthracycline including HER2 TOP2A.
The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab standard neoadjuvant chemotherapy in HER2-negative early breast cancer.
Aromatase inhibitors (AIs) have an established role in the treatment of breast cancer. Response rates are only 50% to 70% neoadjuvant setting and lower advanced disease. Accurate biomarkers urgently needed predict response these settings determine which individuals will benefit from adjuvant AI therapy.
Patients with early-stage breast cancer, treated endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite additional adjuvant such as chemotherapy, may be indicated. The challenge is to prospectively identify patients. Mammostrat® test uses five immunohistochemical markers stratify on tamoxifen therapy into groups inform treatment decisions. We tested the efficacy this panel in a mixed population cases single center...
Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared those non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, topoisomerase IIalpha expression are predictive of outcome after anthracycline-based...
// Carol Ward 1 , James Meehan Peter Mullen 2 Claudiu Supuran 3 J. Michael Dixon 4 Jeremy S. Thomas 5 Jean-Yves Winum 6 Philippe Lambin 7 Ludwig Dubois Nanda-Kumar Pavathaneni 6, Edward Jarman Lorna Renshaw InHwa Um Charlene Kay David Harrison Ian H. Kunkler 8 Simon P. Langdon Division of Pathology, Institute Genetics and Molecular Medicine, University Edinburgh, United Kingdom School St Andrews, North Haugh, Università degli Studi di Firenze, Polo Scientifico, Laboratorio Chimica...
BACKGROUND--A study was undertaken to investigate the accuracy of typing a series bronchial carcinomas by experienced pathologists with an interest in lung cancer from examination bronchoscopic biopsy specimens. METHODS--Eighty specimens showing positive results for carcinoma were circulated five pathologists, who recorded diagnostic criteria and diagnosis each. Diagnoses then compared agreed resection specimen corresponding each specimen. A "non-small cell carcinoma, not further specified"...
The guidelines for follow-up of breast cancer patients concentrate on the first 3-5 years, with either reduced frequency visits or discharge after this. They also recommend mammography, but no evidence exists to inform frequency. We analyse treatable relapses in our unit from 1312 early stage treated by conserving surgery (BCS) and postoperative radiotherapy between 1991 1998 assess appropriateness guidelines. A total 110 were analysed. Treatable relapse developed at 1-1.5% per year...
Abstract Background The Sloane audit compares screen-detected ductal carcinoma in situ (DCIS) pathology with subsequent management and outcomes. Methods This was a national, prospective cohort study of DCIS diagnosed during 2003–2012. Results Among 11,337 patients, 7204 (64%) had high-grade DCIS. Over time, the proportion disease increased (from 60 to 65%), low-grade decreased 10 6%) mean size 21.4 24.1 mm). Mastectomy more common for (36%) than (15%). Few (6%) patients treated...
Epigenetic changes are being increasingly recognized as a prominent feature of cancer. This occurs not only at individual genes, but also over larger chromosomal domains. To investigate this, we set out to identify large domains epigenetic dysregulation in breast cancers.We regions coordinate down-regulation gene expression, and other activation, cancers show that these linked tumor subtype. In particular group coordinately regulated expressed luminal, estrogen-receptor positive tumors cell...
The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) overall (OS) with central pathology review.Patients were randomized 3 cycles D FEC (D-FEC), ±4 Bev (Bev + D-FEC). DFS OS analyzed treatment reviewed pCR Residual Cancer Burden (RCB) class.A total 800...
We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer. The clinical validity of this finding independent studies, among patients receiving different chemotherapy, unknown.
The Nottingham Prognostic Index Plus (NPI+) is a clinical decision making tool in breast cancer (BC) that aims to provide improved patient outcome stratification superior the traditional NPI. This study aimed validate NPI+ an independent series of BC. Eight hundred and eighty five primary early stage BC cases from Edinburgh were semi-quantitatively assessed for 10 biomarkers [Estrogen Receptor (ER), Progesterone (PgR), cytokeratin (CK) 5/6, CK7/8, epidermal growth factor receptor (EGFR),...